Clin Exp Vaccine Res.  2013 Jul;2(2):128-134. 10.7774/cevr.2013.2.2.128.

Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model

Affiliations
  • 1Clinical Vaccine R&D Center, Chonnam National University, Gwangju, Korea. selee@chonnam.ac.kr
  • 2Department of Pharmacology and Dental Therapeutics, School of Dentistry, Chonnam National University, Gwangju, Korea.
  • 3Department of Microbiology, Chonnam National University Medical School, Gwangju, Korea.

Abstract

PURPOSE
Human papillomavirus (HPV) is a significant cause of cervical cancer-related deaths worldwide. Because HPV is a sexually transmitted mucosal pathogen, enhancement of antigen-specific mucosal immune response likely serves good strategy for vaccination. However, mucosal vaccines generally do not induce strong enough immune responses. Previously we proved that a bacterial flagellin, Vibrio vulnificus FlaB, induce strong antigen-specific immune responses by stimulating the Toll-like receptor 5. In this study, we tested whether FlaB could serve as an effective mucosal adjuvant for a peptide-based HPV preventive cancer vaccine.
MATERIALS AND METHODS
Mice were intranasally administered with a mixture of FlaB and E6/E7 protective peptides in 5-day interval for a total of two times. Five-days after the last vaccination, cellular immune responses of the vaccinated mice were analyzed. Tumor growth was also observed after a subcutaneous implantation of TC-1 cells bearing E6/E7 antigens.
RESULTS
Intranasal administration of the E6/E7 peptide mixture with FlaB elicited a strong antigen-specific cytotoxic T lymphocyte activity and antigen-specific interferon-gamma production from splenocytes and cervical lymph node cells. Furthermore, FlaB, as a mucosal adjuvant, conferred an excellent protection against TC-1 tumor challenge with high survival rates in E6/E7 immunized animals.
CONCLUSION
These results indicate that FlaB can be a promising mucosal adjuvant for nasal HPV vaccine development.

Keyword

Flagellin; Adjuvant; Neoplasms; Vaccines

MeSH Terms

Administration, Intranasal
Animals
Flagellin
Humans
Immunity, Cellular
Immunity, Mucosal
Immunization
Interferon-gamma
Lymph Nodes
Lymphocytes
Mice
Peptides
Survival Rate
Toll-Like Receptor 5
Ursidae
Vaccination
Vaccines
Vibrio vulnificus
Flagellin
Interferon-gamma
Peptides
Toll-Like Receptor 5
Vaccines

Figure

  • Fig. 1 FlaB enhances antigen-specific cytotoxic T lymphocyte (CTL) responses. Each group of vaccinated mice (n = 5) was sacrificed at day 10. The splenocytes (SPL) were prepared to determine the CTL activity in vitro. To prepare the effector cells, SPLs were stimulated in vitro with E6/E7 peptides (1 µg/mL each) in the presence of interleukin-2 (25 IU/mL) for 5 days. The TC-1 cells were treated with cisplatin (1 µg/mL) for 24 hours and then used as the target cells. The effector and target cells were co-cultured at various effector:target (E:T) cell ratios. After 5-hour incubation at 37℃, 50 µL of the cell supernatant was collected to measure the lactate dehydrogenase activity in the culture medium. The ANOVA was used to compare CTL responses. *p < 0.05.

  • Fig. 2 Interferon-γ (IFN-γ) production from splenocytes and cervical lymph node cells. Each group of vaccinated mice (n = 5) was sacrificed at day 10. The splenocytes (A) and cervical lymph node cells (B) were prepared to determine IFN-γ production. Immune cells were stimulated in vitro with the E6/E7 peptides (1 µg/mL each) for 3 days. The number of E6/E7 peptide-specific IFN-γ producing cells generated in vaccinated mice was determined by group by ELISPOT assay. The Student's t-test was used to compare the IFN-γ production between two groups. *p < 0.05 and **p < 0.01.

  • Fig. 3 Prophylactic antitumor effect of flagellin-adjuvanted peptide based vaccine. Groups of 5 vaccinated mice were subcutaneously challenged with 5 × 105 TC-1 tumor cells at 5 days after the last vaccination. Changes in tumor sizes (A) and mouse survival rates (B) were monitored at 3-day intervals. The statistical significance of tumor volume at 21 days after TC-1 cell challenge was determined by the Student's t-test. The survival curve was constructed according to the Kaplan-Meier method, and the statistical significance between P and P + F group was determined by the log-rank test. *p < 0.05 and **p < 0.01.


Reference

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74–108.
Article
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189:12–19.
Article
3. Kim D, Gambhira R, Karanam B, et al. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine. 2008; 26:351–360.
Article
4. Lin K, Doolan K, Hung CF, Wu TC. Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc. 2010; 109:4–24.
Article
5. Roden RB, Ling M, Wu TC. Vaccination to prevent and treat cervical cancer. Hum Pathol. 2004; 35:971–982.
Article
6. Mahdavi A, Monk BJ. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist. 2005; 10:528–538.
Article
7. Sin JI, Kim JM, Bae SH, Lee IH, Park JS, Ryoo HM. Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway. Mol Ther. 2009; 17:906–913.
Article
8. Manuri PR, Nehete B, Nehete PN, et al. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine. 2007; 25:3302–3310.
Article
9. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol. 2002; 169:350–358.
Article
10. Vambutas A, DeVoti J, Nouri M, et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine. 2005; 23:5271–5280.
Article
11. Sharma RK, Elpek KG, Yolcu ES, et al. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res. 2009; 69:4319–4326.
Article
12. Lee SE, Kim SY, Jeong BC, et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun. 2006; 74:694–702.
Article
13. Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine. 2011; 29:5731–5739.
Article
14. Hong SH, Byun YH, Nguyen CT, et al. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine. 2012; 30:466–474.
Article
15. Rhee JH, Lee SE, Kim SY. Mucosal vaccine adjuvants update. Clin Exp Vaccine Res. 2012; 1:50–63.
Article
16. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993; 23:2242–2249.
Article
17. Seo SH, Kim KS, Park SH, et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther. 2011; 18:488–495.
Article
18. Yu YA, Shabahang S, Timiryasova TM, et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol. 2004; 22:313–320.
Article
19. Bae SH, Park YJ, Park JB, Choi YS, Kim MS, Sin JI. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res. 2007; 13:341–349.
Article
20. Sin JI. MyD88 signal is required for more efficient induction of Ag-specific adaptive immune responses and antitumor resistance in a human papillomavirus E7 DNA vaccine model. Vaccine. 2011; 29:4125–4131.
Article
21. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001; 410:1099–1103.
Article
22. Ramos HC, Rumbo M, Sirard JC. Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa. Trends Microbiol. 2004; 12:509–517.
Article
23. Seo SH, Jin HT, Park SH, Youn JI, Sung YC. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine. 2009; 27:5906–5912.
Article
24. Crellin NK, Garcia RV, Hadisfar O, Allan SE, Steiner TS, Levings MK. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J Immunol. 2005; 175:8051–8059.
Article
25. Rhee SH, Im E, Pothoulakis C. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology. 2008; 135:518–528.
Article
26. Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 2011; 71:2466–2475.
Article
27. Sfondrini L, Rossini A, Besusso D, et al. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol. 2006; 176:6624–6630.
Article
Full Text Links
  • CEVR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr